Wolverine Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Wolverine Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.71M	Sell	22,815 -7,700	-25%	-$608K	0.02%	613
2025 Q4	$2.41M	Buy	+30,515	New	+$2.3M	0.02%	545
2021 Q3	–	Sell	-783	Closed	-$29.5K	–	2162
2021 Q2	$31K	Buy	+783	New	+$30.7K	﹤0.01%	1796
2020 Q3	–	Sell	-32	Closed	-$1.78K	–	1653
2020 Q2	$1K	Buy	+32	New	+$1.78K	﹤0.01%	1493
2017 Q1	–	Sell	-187,742	Closed	-$8.43M	–	1277
2016 Q4	$8.98M	Buy	+187,742	New	+$7.43M	0.12%	158

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wolverine Asset Management's IONS Position: Q1 2026 in Review

Wolverine Asset Management reduced its Ionis Pharmaceuticals (IONS) stake by 25% in Q1 2026, selling an estimated $608K and leaving 22,815 shares worth $1.71M. The position accounts for 0.02% of the portfolio, ranked #613.

Wolverine Asset Management first reported a position in IONS in Q4 2016 and has held it in 5 quarters since. The position peaked at $8.98M in Q4 2016. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Wolverine Asset Management held 22,815 shares of Ionis Pharmaceuticals worth $1.71M as of Q1 2026.
Wolverine Asset Management sold 7,700 Ionis Pharmaceuticals shares in Q1 2026, an estimated $608K.
Ionis Pharmaceuticals made up 0.02% of Wolverine Asset Management's portfolio in Q1 2026, its #613 holding.
Wolverine Asset Management first reported a position in Ionis Pharmaceuticals in Q4 2016 and has held it in 5 quarters since.
Wolverine Asset Management's Ionis Pharmaceuticals position peaked at $8.98M in Q4 2016.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.